Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Development of Japan-Made Vaccines “Significantly Meaningful”: Minister
April 12, 2021
- MSD’s Recarbrio Up for PAFSC Review on April 21
April 8, 2021
- Label Update Will Suffice to Expand COVID-19 Vaccination Age: MHLW Official
April 7, 2021
- AMED to Set Up Council to Hone Academic Seeds with Industry Input
April 7, 2021
- MHLW Launches New Office to Fuel SaMD Commercialization
April 6, 2021
- MHLW to Consider Ways to Address Listing Delays Linked to Off-Year Re-Pricing: Official
April 6, 2021
- Nichi-Iko’s Toyama Plant Gets Back Online as Suspension Order Lifted
April 6, 2021
- 1st Vaccine Doses to Be Delivered for Half of Elderly by May: Kono
April 5, 2021
- Ex-PMDA Inspector Urges Improvements in Japanese Inspection Systems after GMP Scandals
April 5, 2021
- Japan Mulls Expanding COVID-19 Vaccination Age to 12-15
April 5, 2021
- MHLW Calls for Thiola’s Priority Use for Cystinuria as Shortage Expected
April 2, 2021
- Neurosurgical Expert Eager to Carry Out Bridging Study of Cannabis-Derived Drug in Japan
April 2, 2021
- Japan Publishes Cost-Effectiveness Analysis Reports for Kymriah, Trelegy
April 1, 2021
- Japan to Research Duration of COVID-19 Vaccine Efficacy: Minister
March 31, 2021
- Label Revisions Ordered for Utemerin and More Drugs, 1st Update for Zolgensma
March 31, 2021
- 1.35% of Tokyo Residents Have Coronavirus Antibodies: MHLW
March 31, 2021
- Govt’s Drug Development Panel Adopts 5 Priority Topics for Discussion
March 31, 2021
- Govt to Set Up Taskforce to Spur Development of Japan-Made Vaccines
March 30, 2021
- Japan Gives Up on Setting New Generic Target by March as Manufacturing Scandals Weigh
March 30, 2021
- LDP League Submits Request to Reinstate HPV Vaccine Promotion
March 30, 2021
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…